CClinicalTrials.gg
TerminatedNCT00987428EEPAB2Updated Nov 20, 2025

Early Endoscopic Ultrasound - Based Sphincterotomy or Conservative Treatment in Severe Biliary Pancreatitis

An interventional study of ultrasonography with or not sphincterotomy and Usual procedure in Pancreatitis Acute Biliary, sponsored by Assistance Publique - Hôpitaux de Paris. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

Why this study was terminated
Insufficient number of participants
Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this trial is to determine whether an early Early Endoscopic Ultrasound (EUS) immediately followed by an endoscopic sphincterotomy (ES) in case of bile duct stones may improve outcomes in patients with predicted severe acute biliary pancreatitis (ABP).

Read the detailed description

The management of Acute biliary pancreatitis (ABP) remains controversial. Although early decompression of the bile duct is deemed potentially beneficial, previous randomised studies failed to show the benefit of early endoscopic sphincterotomy (ES) except in selected cases. However, those studies did not use recent non invasive diagnostic methods such as EUS.

Methodology: Patients in the study group undergo EUS followed by ES in case of common bile duct stones within 48 hours of the onset pf symptoms; The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.

02

Conditions studied

  • Pancreatitis Acute Biliary

Browse trials for

Keywords

  • ERCP
  • EUS
  • Pancreatitis biliary
  • Severe
  • Interventional endoscopy
  • Choledocolithiasis
03

In context

Lymphoma, Follicular

931 studies on the registry are indexed under Lymphoma, Follicular; 237 are open to participants now.

This study's enrollment of 27 is below the median of 48 across 797 interventional studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • age > 18
  • predicted severe acute biliary pancreatitis (including age > 80, BMI >30, pre-existing organ failure, Modified Glasgow score > 3)
  • timespan between onset and randomization \< 48 hrs
  • informed consent signed by patient or liable person in case of emergency

Exclusion criteria

Exclusion criteria :

  • non biliary pancreatitis
  • non severe pancreatitis
  • age \< 18
  • timespan between onset and randomization > 48 hrs
  • absence of consent
  • ongoing pregnancy
  • no social security insurance
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    groupe 1

    Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone

    Procedure: ultrasonography with or not sphincterotomy

  • Active comparator
    Groupe 2

    usual procedure

    Procedure: Usual procedure

Interventions

  • Procedureultrasonography with or not sphincterotomy

    Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone

  • ProcedureUsual procedure

    The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.

06

What researchers measure

Primary outcomes

  1. The difference between the SOFA score measured at entry in the study (day 0) and at day 8

    Time frame: Day 8

Secondary outcomes

  1. Differences in SOFA score as measured at entry in the study and at day 15

    Time frame: Day 15

  2. Procedure-related morbidity

    Time frame: at Day 15 to 3 months

  3. Overall morbidity

    Time frame: at day 15

  4. Overall mortality

    Time frame: at day 15

  5. Difference in Balthazar's scores (CT-scan) at entry and at days 8 and 15

    Time frame: at day 8 and day 15

07

Study locations

1 site
  • Hopital Cochin
    Paris, 75014, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00987428
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Oct 1, 2009
Start date
Aug 2009
Primary completion
Jun 2011
Completion
Mar 2012
Last update
Nov 20, 2025

Study contacts

Frederic Prat, MD, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion